Streetbeat News

Revenues

GH

Guardant Health reported preliminary Q4 revenue of $153M-$154M, surpassing the estimate of $146.34M. For FY23, the company expects revenue of $562M-$563M, also exceeding the forecast of $555.18M.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:03 pm

INCY

Incyte (NASDAQ:INCY) presented at the 42nd Annual J.P. Morgan Healthcare Conference, highlighting growth opportunities and updates in its pipeline. The company announced positive Phase 2 results for ruxolitinib cream (Opzelura) in treating hidradenitis suppurativa (HS) and plans for a Phase 3 study. Incyte also showcased early data for INCB123667, a CDK2 inhibitor showing promise in late-stage cancers. Updates on expanding leadership in MPNs and GVHD, as well as the dermatology franchise, were provided. Further financial guidance and clinical program updates are expected in the 2023 Q4 earnings call.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:02 pm

HNRA

HNR Acquisition Corp (NYSE:HNRA) announced its 2024 operational plan, expecting increased production and revenues due to cost control and optimized production. The company completed the acquisition of the Grayburg-Jackson oil field over 45 days ago, which has been profitable with positive cash flow for the last two years. HNRA plans to reduce idle well count, enhance oil production, and improve financials by implementing new workovers, maintenance, and repairs. The company aims to increase production by 100 barrels of oil per day at minimal cost and has identified ten low-cost opportunities to further improve production.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:02 pm

AGL

Agilon Health (NYSE:AGL) received mixed ratings from 10 financial analysts, with a shift towards more bearish sentiment over the past three months. The average 12-month price target is now $18.3, down from $24.75, with a high estimate of $28.00 and a low of $9.00. Analysts from firms including Truist Securities, JP Morgan, JMP Securities, Deutsche Bank, Benchmark, Wells Fargo, Goldman Sachs, and RBC Capital have adjusted their ratings and price targets. Agilon Health's financial performance shows strong revenue growth but below-average profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:01 pm

FDX

Five analysts have recently updated their ratings on FedEx (NYSE:FDX), with a mix of bullish and neutral stances. The average 12-month price target is now $304.00, down from the previous $315.25. Analysts from Melius Research, Stephens & Co., Raymond James, Barclays, and JP Morgan have adjusted their price targets, with four lowering their estimates and one announcing a new 'Buy' rating. FedEx's financials show a slight revenue decline, strong net margin, ROE, and ROA, and a healthy debt-to-equity ratio. These updates may influence investors' perceptions of FedEx's stock performance in the short term.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:00 pm

ENOV

Analysts have provided mixed reviews on Enovis (NYSE:ENOV) over the past three months, with 6 bullish ratings, including recent updates to price targets and ratings. The average 12-month price target for Enovis is now $70.17, up from $66.75, with a high estimate of $75.00 and a low of $62.00. Enovis is a medical technology company with segments in Prevention & Recovery and Reconstructive surgery, showing strong revenue growth and financial performance despite a lower market capitalization compared to industry peers.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:00 pm

TPCS

TechPrecision Corporation (NASDAQ:TPCS) announced the expiration of the 45-day diligence period for the acquisition of Votaw Precision Technologies, Inc., committing to the closing of the acquisition. The Board, owning over 15% of TechPrecision stock, unanimously supports the acquisition, which is expected to bring synergy, growth, overhead savings, and CAPEX savings. The merger is anticipated to raise revenue and provide cost savings, with STADCO's operations moving to Votaw's facility. TechPrecision will seek debt and equity financing for the acquisition, with details to be determined by market conditions. Full financial details from Votaw will be disclosed after the fiscal year ending October 31, 2023.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:00 pm

AXP

Analysts have provided mixed evaluations for American Express (NYSE:AXP) over the last three months, with a total of 14 ratings ranging from bullish to bearish. The average 12-month price target for AXP is $179.36, with a high of $205.00 and a low of $151.00, marking a slight decrease from the previous average of $180.88. Recent actions by analysts include various rating adjustments and price target changes. American Express, a global financial services company, has shown strong financial performance with a revenue growth rate of 13.57%, a net margin of 15.76%, an ROE of 8.95%, an ROA of 0.98%, and a debt-to-equity ratio of 1.76.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:00 pm

LUV

Southwest Airlines (NYSE:LUV) has been rated by 8 analysts in the last three months, with a mix of sentiments. The average 12-month price target is $29.75, down from $31.57. Analysts from firms like Bernstein, Evercore ISI Group, Citigroup, Raymond James, Susquehanna, Morgan Stanley, and TD Cowen have adjusted their ratings and price targets. Southwest's financials show a market cap that asserts its dominance, a revenue growth of 4.9%, a net margin of 2.96%, an ROE of 1.77%, an ROA of 0.53%, and a debt-to-equity ratio of 0.84.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:00 pm

MQ

Marqeta (NASDAQ:MQ) has received mixed analyst ratings over the past three months, with 7 analysts offering a range of opinions. The average 12-month price target has risen to $7.5, up 13.29% from the previous $6.62. Analysts from Keybanc, Truist Securities, Mizuho, Morgan Stanley, Susquehanna, Wells Fargo, and UBS have updated their ratings and price targets, reflecting a generally positive outlook. Marqeta, a card-issuing platform provider, has seen a revenue decline of -43.17% and faces challenges with market capitalization, net margin, ROE, and ROA, despite a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:00 pm